Plain-English translation of NCT06374875 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether weight loss surgery or injectable medications—specifically semaglutide, tirzepatide, or liraglutide—work better at treating advanced fatty liver disease with scarring. You would be randomly assigned to either have weight loss surgery or take one of these injected medications for 2 years, with doctors checking your liver health through biopsies at the start and end.
Fatty liver disease with scarring is a serious condition affecting many people with obesity, but doctors aren't sure whether surgery or the newer injectable medications work better. This study will help answer that question by comparing them directly.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to either have weight loss surgery or start taking one of the injectable medications. Either way, you'll visit the clinic regularly for 2 years to check your health and weight. You'll have a liver biopsy (a small needle sample of liver tissue) at the beginning and again after 2 years so doctors can see if your liver disease improved.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Brazil